4.6 Article

Mutation spectrum of FLT3 and significance of non-canonical FLT3 mutations in haematological malignancy

Journal

BRITISH JOURNAL OF HAEMATOLOGY
Volume -, Issue -, Pages -

Publisher

WILEY
DOI: 10.1111/bjh.18877

Keywords

FLT3; FLT3 inhibitor; haematological malignancy; kinase activity; mutation spectrum

Categories

Ask authors/readers for more resources

In this study, the spectrum of FLT3 mutations in haematological malignancies was investigated. Four types of non-canonical FLT3 mutations were identified, including non-canonical point mutations, deletion, frameshift, and ITD outside the JMD and TKD1 regions. The survival of patients with high-frequency FLT3-NCPM in AML was shown to be comparable to those with canonical TKD mutations. Additionally, certain deletion and ITD mutants showed higher kinase activity than wild-type FLT3, and all tested deletion mutations and ITD were sensitive to AC220 and sorafenib.
Fms-like tyrosine kinase 3 (FLT3) is frequently mutated in haematological malignancies. Although canonical FLT3 mutations including internal tandem duplications (ITDs) and tyrosine kinase domains (TKDs) have been extensively studied, little is known about the clinical significance of non-canonical FLT3 mutations. Here, we first profiled the spectrum of FLT3 mutations in 869 consecutively newly diagnosed acute myeloid leukaemia (AML), myelodysplastic syndrome and acute lymphoblastic leukaemia patients. Our results showed four types of non-canonical FLT3 mutations depending on the affected protein structure: namely non-canonical point mutations (NCPMs) (19.2%), deletion (0.7%), frameshift (0.8%) and ITD outside the juxtamembrane domain (JMD) and TKD1 regions (0.5%). Furthermore, we found that the survival of patients with high-frequency (>1%) FLT3-NCPM in AML was comparable to those with canonical TKD. In vitro studies using seven representative FLT3-deletion or frameshift mutant constructs showed that the deletion mutants of TKD1 and the FLT3-ITD mutant of TKD2 had significantly higher kinase activity than wild-type FLT3, whereas the deletion mutants of JMD had phosphorylation levels comparable with wild-type FLT3. All tested deletion mutations and ITD were sensitive to AC220 and sorafenib. Collectively, these data enrich our understanding of FLT3 non-canonical mutations in haematological malignancies. Our results may also facilitate prognostic stratification and targeted therapy of AML with FLT3 non-canonical mutations.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available